ZOETIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 174 USD | +0.18% |
|
+2.95% | -11.83% |
| 08/05 | HSBC Adjusts Price Target on Zoetis to $225 From $230 | MT |
| 06/05 | BNP Paribas Exane Adjusts Price Target on Zoetis to $232 From $237 | MT |
Presenter SpeechBill Price (Executives)Good morning, everyone, and welcome to the 2017 Annual ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows:
- pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%);
- livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%);
- other (1.1%).
Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%).
At the end of 2022, the group has 29 production sites worldwide.
The United States accounts for 53.4% of net sales.
Sector
Pharmaceuticals
Calendar
22/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
174.1
USD
Average target price
211.2
USD
Spread / Average Target
+21.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.83% | 79.42B | |
| +28.00% | 3.8B | |
| -1.39% | 3.23B | |
| +21.28% | 1.75B | |
| -3.25% | 1.61B | |
| -18.63% | 1.36B | |
| -1.17% | 1.3B | |
| -6.77% | 1.22B | |
| +2.34% | 1.11B | |
| +2.26% | 1.07B |
- Stock Market
- Equities
- ZTS Stock
- News Zoetis Inc.
- Transcript : Zoetis Inc. - Shareholder/Analyst Call
